Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Phosphoproteomics is a promising tool for identifying biomarkers of treatment response in cancer. Here, the authors analyse proteomics profiling of HER2-negative female breast cancer patients and identify potential predictors of paclitaxel response.
Bibliographic Details
| Main Authors: |
S. Mouron,
M. J. Bueno,
A. Lluch,
L. Manso,
I. Calvo,
J. Cortes,
J. A. Garcia-Saenz,
M. Gil-Gil,
N. Martinez-Janez,
J. V. Apala,
E. Caleiras,
Pilar Ximénez-Embún,
J. Muñoz,
L. Gonzalez-Cortijo,
R. Murillo,
R. Sánchez-Bayona,
J. M. Cejalvo,
G. Gómez-López,
C. Fustero-Torre,
S. Sabroso-Lasa,
N. Malats,
M. Martinez,
A. Moreno,
D. Megias,
M. Malumbres,
R. Colomer,
M. Quintela-Fandino |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Portfolio
2022-12-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-022-35065-z
|
|---|